Abstract
Esophageal (EC) and gastric (GC) cancers represent severe global health issues. Within the last 18 months, the standard of care has significantly evolved for the first-line setting of advanced EC and GC within the field of human epidermal growth factor receptor 2 (HER2)-negative and HER2-positive patients. The breakthrough concepts for clinical practice of immune checkpoint inhibitors (ICIs) plus chemotherapy in both fields were presented at major oncology meetings over the last 2 years. This review summarizes the latest results on when and how to use the new combinations and highlights the unsolved issues in this new era.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
